Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane

@article{Park2014PhaseIG,
  title={Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane},
  author={Ji Soo Park and Hei-Cheul Jeung and Sun Young Rha and Joong Bae Ahn and Beodeul Kang and Hong Jae Chon and Min Hee Hong and Seungtaek Lim and Woo Ick Yang and Chung Mo Nam and Hyun Cheol Chung},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2014},
  volume={74},
  pages={799-808}
}
We conducted a phase II study evaluating safety and efficacy of combination gemcitabine and capecitabine therapy for metastatic breast cancer patients following anthracycline and taxane treatment in Korea. This was a single-arm, non-randomized phase II study. Patients received 1,000 mg/m2 gemcitabine intravenously over 30 min on days 1 and 8, and 1,250 mg/m2 capecitabine orally twice daily on days 1–14 until disease progression or intolerable toxicity occurred. This regimen was repeated every 3… CONTINUE READING
2 Extracted Citations
39 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 39 references

Gemcitabine ( G ) plus capecitabine ( C ) in previously treated metastatic breast cancer ( MBC ) patients . Final results from a phase II GOTI trial

  • A Malmström, J Hansen, +6 authors R Westberg
  • Breast Cancer Res Treat
  • 2010

Similar Papers

Loading similar papers…